Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 3, 2011, Pages 732-736

  Dibiase, Steven J ^a   Hussain, Arif ^b   Kataria, Ritesh ^b   Amin, Pradip ^b   Bassi, Sunakshi ^b   Dawson, Nancy ^c   Kwok, Young ^b  

^a Department of Anesthesiology   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant docetaxel; Brachytherapy; Multimodality; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN ABLATIONS; BIOCHEMICAL FAILURE; BRACHYTHERAPY; DISEASE FREE SURVIVAL; DOCETAXEL; EXTERNAL RADIATION; FREEDOM FROM BIOCHEMICAL FAILURES; GASTROINTESTINAL TOXICITIES; GLEASON SCORES; HEMATOLOGIC TOXICITY; IODINE-125; LONG-TERM ANDROGEN DEPRIVATION; MULTI-MODALITY; OVERALL SURVIVAL RATES; PELVIC RADIOTHERAPY; PHASE II; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

CHEMOTHERAPY; DISEASES; IODINE; ONCOLOGY; TOXICITY;

RADIOTHERAPY;

BICALUTAMIDE; DOCETAXEL; FLUTAMIDE; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; STEROID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER RISK; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NOCTURIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT FAILURE; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PELVIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; TAXOIDS;

EID: 80053599473     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.06.042     Document Type: Article

References (21)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
2. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504 Epub 2008 Apr 14
3. G.K. Zagars, A. Pollack, and L.G. Smith Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate Int J Radiat Oncol Biol Phys 44 1999 809 819 (Pubitemid 29284129)
4. M.J. Zelefsky, W.K. Kelly, and H.I. Scher Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer J Clin Oncol 18 2000 1936 1941 (Pubitemid 30261932)
5. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
6. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
7. A.L. Zietman Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate JAMA 299 2008 898 900
8. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327 333 (Pubitemid 46108308)
9. J.E. Sylvester, P.D. Grimm, and J.C. Blasko 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience Int J Radiat Oncol Biol Phys 67 2007 57 64 (Pubitemid 44959493)
10. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
11. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
12. A.L. Hanlon, T.E. Schultheiss, and M.A. Hunt Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales Int J Radiat Oncol Biol Phys 387 1997 59 63 (Pubitemid 27270943)
13. C.A. Pettaway, L.L. Pisters, and P. Troncoso Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results J Clin Oncol 18 2000 1050 1057 (Pubitemid 30123782)
14. B. Mellado, A. Font, and A. Alcaraz Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer Br J Cancer 101 2009 1248 1252
15. J. Vuky, C. Porter, and C. Isacson Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer Cancer 115 2009 784 791
16. D.R. Shepard, R. Dreicer, and J. Garcia Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy J Urol 181 2009 1672 1677 discussion 1677
17. J.A. Eastham, W.K. Kelly, and G.D. Grossfeld Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease Urology 62 Suppl 1 2003 55 62 (Pubitemid 41116563)
18. C.J. Ryan, M.J. Zelefsky, and G. Heller Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer Urology 64 2004 90 94 (Pubitemid 38887585)
19. P. Kumar, M. Perrotti, and R. Weiss Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate J Clin Oncol 22 2004 1909 1915 (Pubitemid 41095183)
20. M. Perrotti, T. Doyle, and P. Kumar Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10) Urol Oncol 26 2008 276 280 (Pubitemid 351608579)
21. B. Carey, and S. Swift The current role of imaging for prostate brachytherapy Cancer Imaging 7 2007 27 33 (Pubitemid 47528075)